The PPARpan agonistscan activate all three PPAR subtypes, and they can potentially exert variouseffects on metabolic disorders such as insulin resistance, obesity,dyslipidemia, and hypertension. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.